65.57
4.01 (6.51%)
| Penutupan Terdahulu | 61.56 |
| Buka | 61.74 |
| Jumlah Dagangan | 1,931,647 |
| Purata Dagangan (3B) | 1,209,331 |
| Modal Pasaran | 3,208,465,152 |
| Harga / Buku (P/B) | 78.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2026 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Celcuity Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 0.67 |
|
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Jun 2026 | 1,451,014 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |